# Cetosomes.com — Dermal Encapsulation & Cetosome® Delivery Technology > Scientific reference on dermal encapsulation, lipid nanovesicle entrapment and Cetosome® nanovesicles: self-assembling particles of cetylated fatty esters, cetyl/stearyl alcohols, surfactants and polar solvents (US 9,084,818 B2; US 8,394,759 B2). Measured diameter 60–850 nm; claimed zeta potential −20 to −100 mV (measured −22 to −55 mV); real-time stability 18–26 months at 25 °C/65% RH; dual hydrophilic + lipophilic loading; gradual release over up to 24 h. Key facts (with sources): - Patent: US 9,084,818 B2 (Cymbiotics, Inc.; granted 2015-07-21), claim 1 composition and zeta potential. - Clinical: Sattur et al., Cureus 2023;15(10):e46568, PMID 37937040 — randomised cetosomal vs alcohol-based 5% minoxidil; adverse events 9% vs 41% (p = 0.02). - Clinical: Kerure et al., Cureus 2023;15(7):e41681, PMID 37575862 — retrospective, 66 centres, n = 261; 1 treatment-related adverse event (0.3%). - Limitations: small or retrospective, industry-affiliated studies in minoxidil; no head-to-head trials yet for cetosomal retinoids or acids. ## Core pages - [Understand the Technology](https://cetosomes.com/understand-the-technology): four-stage penetration pathway, 24-hour release profile, specifications - [Normal vs Cetosome®](https://cetosomes.com/normal-vs-cetosome): moisturiser/serum comparison, molecule-by-molecule trade-offs, limitations - [Clinical Adoption](https://cetosomes.com/clinical-adoption): tolerability and adherence data for clinicians; [dossier](https://cetosomes.com/clinical-adoption/dossier) - [Beyond Dermatology](https://cetosomes.com/beyond-dermatology): transdermal analgesics, hormones, patch replacement - [Patent & Origin](https://cetosomes.com/patent-and-origin): patent lineage, stability validation, origin - [Contact](https://cetosomes.com/contact): WhatsApp enquiry templates for products, clinics, literature dossier, licensing and calls - [Glossary](https://cetosomes.com/glossary): definitions of nanocarrier and encapsulation terms ## Research Journal - [Hydrophilic + Lipophilic Co-Loading: How Dual-Solubility Nanocarriers Deliver Multi-Active Formulations in One Step](https://cetosomes.com/journal/hydrophilic-lipophilic-co-loading-dual-solubility-nanocarriers): Dual-solubility nanocarriers hold water-soluble actives in polar or aqueous domains and oil-soluble actives in lipid lamellae within the same particle. One vehicle can then deliver molecules such as niacinamide and a retinoid together, at controlled ratios, without separate serums and creams. Cetosomes® do this through a polar mantle around a cetylated lamellar core. - [Vehicle Engineering in Clinical Dermatology: Reducing Retinoid & Acid Drop-Off Through 24-Hour Controlled Release](https://cetosomes.com/journal/vehicle-engineering-retinoid-acid-drop-off-controlled-release): Retinoids and topical acids most often fail through early discontinuation, not lack of efficacy. Dryness, peeling, erythema and stinging peak in the first weeks, when patients decide whether to continue. Controlled-release nanovesicle vehicles flatten the early concentration spike and support the barrier, which addresses the leading cause of drop-off without changing the active. - [Why K-Beauty Formulators Are Hunting for Low-Cost Alternatives to Pharmaceutical Lipid Nanovesicles](https://cetosomes.com/journal/k-beauty-low-cost-alternatives-pharmaceutical-lipid-nanovesicles): Pharmaceutical-grade lipid nanovesicles cost more because of controlled thermal processing, high-shear emulsification, particle-size and zeta-potential release testing, and 18–26 months of real-time stability work. Fast-cycle cosmetic brands launch on short timelines with low unit costs. Many therefore choose cheaper carriers, or marketing-led ingredients such as ‘exosomes’, over licensed, fully characterised systems. - [Zeta Potential (-20mV to -100mV) Explained: Why Most Liposomal Serums Clump and Degrade on the Shelf](https://cetosomes.com/journal/zeta-potential-explained-liposomal-serum-stability): Zeta potential is the electrical potential at the slipping plane around a particle in liquid, and it indicates how strongly neighbouring particles repel. Dispersions beyond about ±25–30 mV usually resist clumping, while near-neutral vesicles aggregate, fuse and leak. Cetosome® nanoparticles are claimed at −20 to −100 mV, with −22 to −55 mV measured across formulations. - [Why 15% Unencapsulated Azelaic Acid Stings—And How Lipid Bilayer Entrapment Solves Stratum Corneum Irritation](https://cetosomes.com/journal/why-azelaic-acid-stings-lipid-bilayer-entrapment): Azelaic acid stings because a 15–20% dicarboxylic acid load meets the skin all at once, raising local acidity and stimulating nerve endings, especially where the barrier is already compromised. Entrapping the acid in lipid nanovesicles lowers the free fraction at the surface and releases it gradually. The aim is the same total dose with a smaller, slower peak. - [Cetosomes® vs. Exosomes in Topical Skincare: Stability, Regulation & Bioavailability Compared](https://cetosomes.com/journal/cetosomes-vs-exosomes-topical-skincare): Cetosomes® are synthetic, self-assembling nanovesicles made from cetylated fatty esters, with measured diameters of 60–850 nm and a claimed zeta potential of −20 to −100 mV. Exosomes are 30–150 nm vesicles released by living cells. For topical delivery, cetosomes have the edge in reproducibility, shelf stability and regulatory clarity. Exosome products face FDA safety warnings. ## Glossary - [500 Dalton rule](https://cetosomes.com/glossary/500-dalton-rule) - [Amphiphilic](https://cetosomes.com/glossary/amphiphilic) - [Burst release](https://cetosomes.com/glossary/burst-release) - [Cetosomal](https://cetosomes.com/glossary/cetosomal) - [Cetosome®](https://cetosomes.com/glossary/cetosome) - [Cetylated fatty esters](https://cetosomes.com/glossary/cetylated-fatty-esters) - [Controlled release](https://cetosomes.com/glossary/controlled-release) - [Dermal encapsulation](https://cetosomes.com/glossary/dermal-encapsulation) - [Entrapment efficiency](https://cetosomes.com/glossary/entrapment-efficiency) - [Ethosome](https://cetosomes.com/glossary/ethosome) - [Exosome](https://cetosomes.com/glossary/exosome) - [Extracellular vesicle (EV)](https://cetosomes.com/glossary/extracellular-vesicle) - [Lamellar phase](https://cetosomes.com/glossary/lamellar-phase) - [Liposome](https://cetosomes.com/glossary/liposome) - [Microsphere](https://cetosomes.com/glossary/microsphere) - [Nanoparticle (topical)](https://cetosomes.com/glossary/nanoparticle) - [Niosome](https://cetosomes.com/glossary/niosome) - [Penetration enhancer](https://cetosomes.com/glossary/penetration-enhancer) - [Polydispersity index (PDI)](https://cetosomes.com/glossary/polydispersity-index) - [Solid lipid nanoparticle (SLN)](https://cetosomes.com/glossary/solid-lipid-nanoparticle) - [Stratum corneum](https://cetosomes.com/glossary/stratum-corneum) - [Topical bioavailability](https://cetosomes.com/glossary/bioavailability) - [Transdermal delivery](https://cetosomes.com/glossary/transdermal-delivery) - [Transfersome](https://cetosomes.com/glossary/transfersome) - [Vehicle (dermatology)](https://cetosomes.com/glossary/vehicle) - [Zeta potential](https://cetosomes.com/glossary/zeta-potential) ## Optional - [RSS feed](https://cetosomes.com/rss.xml) - [Sitemap](https://cetosomes.com/sitemap.xml) - [References (BibTeX)](https://cetosomes.com/dossier.bib)